View online version

Volume 5 | Number 7 | September 2025

EFORT New President 2025-26, Professor Pietro Ruggieri
and the new Board members

During the past EFORT Congress held in Lyon, France, between the 11 and the 13 June 2025, the EFORT General Assembly 2025 took place. In this meeting, the National Delegates voted in the new Board of EFORT.

EFORT is proud to announce the election of Professor Pietro Ruggieri from Italy, as the new President for the 2024-2025 term. 

A distinguished leader in the field of orthopaedics and traumatology, Prof. Ruggieri was officially elected during the 26th EFORT Annual Congress and will lead EFORT towards the 27th EFORT Annual Congress that will take place in Málaga, Spain from 4 to 6 May 2026.

Prof. Ruggieri brings a wealth of experience and a clear vision for the future of musculoskeletal care. A Full Professor and Chairman of the Department of Orthopaedics and Orthopaedic Oncology at the University of Padova, his impressive career spans decades of dedicated work in surgical activity, research, and academia. He is a renowned expert in musculoskeletal oncology, reconstructive surgery, and prostheses.

His academic achievements are extensive, with over 1.000 scientific papers authored, a notable Hirsch Index of 76, and a track record of speaking at more than 900 international congresses. Prior to his EFORT presidency, he held leadership positions as Past President of both the International Society of Limb Salvage (ISOLS) and the European Musculoskeletal Oncology Society (EMSOS) and served as the Scientific Coordinator for EFORT itself.

Prof. Ruggieri’s commitment to education and research, combined with his dedication to fostering international collaboration, will be invaluable to EFORT's mission. We are honored to have him lead the organization and look forward to his contributions in strengthening the quality of orthopaedic care throughout Europe.

To complete the Board elections, the EFORT National Delegates elected Mr. Don McBride from the United Kingdom as Second Vice-President, Prof. José Cordero-Ampuero from Spain as Secretary General and Dr. Marko Ostojič from Croatia as Young Member at large.

Following the elections and the succession of previous members, the new EFORT Board for the period 2025/2026 is as follows:

• EFORT President 2025-26: Prof. Dr. Pietro Ruggieri | Italy.
• First Vice President: Prof. Dr. Rob Nelissen | Netherlands.
• Second Vice President: Mr. Don McBride | United Kingdom.
• Immediate Past President: Prof. Dr. Theofilos Karachalios | Greece
• Secretary General: Prof. José Cordero Ampuero | Spain
• Treasurer: Prof. Gilles Pasquier | France.
• Member at Large: Prof. Dr. Mehmet Demrihan | Türkiye.
• Member at Large: Dr. René Mihalič | Slovenia.
• Member at large: Prof. Dr. Dieter Christian Wirtz | Germany.
• Young Member at Large: Dr. Marki Stojič | Croatia.

We welcome all new Board members, who took their positions immediately after the 26th EFORT Annual Congress in Lyon, and thank all Board members who have left the Board for their hard work and dedication over the past years.

EFORT OPEN REVIEWS

High-quality instructional peer-reviewed articles across 
the entire field of Orthopaedics and Traumatology

LATEST ARTICLES

Management of hindfoot and ankle in Charcot arthropathy

Author: Nicolas Cellier

EOR VOL.10, N° 06, JUNE 2025

Patellar instability: current approach

Author(s): David H Dejour, David Mazy, Tomas Pineda, Nicolas Cance, Michael J Dan, and Edoardo Giovannetti de Sanctis

LATEST ARTICLES

Magnetic resonance imaging of cruciate ligament disorders: current updates

Author(s): Tanda Yang, Yexin Li, Longtao Yang, and Qian Liu

EOR VOL.10, N° 07, JULY 2025

Periprosthetic humeral fractures after shoulder arthroplasty

Author(s): Anna Behrens, Nick Moronga, Milad Farkhondeh Fal, Konrad Mader, Lukas Heilmann, and Till Orla Klatte

LATEST ARTICLES

Efficacy of pericapsular nerve group block for pain control and functional recovery after total hip arthroplasty: a systematic review and meta-analysis of randomized controlled trials

Author(s): Yapeng Li, Feng Li, Zhijie Zhang, Jiayi Guo, and Chen Yue

EOR VOL.10, N° 08, AUGUST 2025

Risk factors and injury prevention strategies for hamstring injuries: a narrative review

Author(s): Akram Hagos, Amaan A Merchant, Babar Kayani, Adam T Yasen, and Fares S Haddad

EFORT e-Learning
Save the date for the upcoming EFORT Educational Webinar!

EFORT WEBINAR | MONDAY 29 SEPTEMBER 2025 | 19:00 CET

BONE LOSS MANAGEMENT IN REVISION HIP REPLACEMENT

The Webinar will be chaired by Prof. Fatih Küçükdurmaz | Department of Orthopedics, Faculty of Medicine, Istinye University | Sarıyer/Istanbul, Türkiye

This EFORT Educational Webinar will focus on provide an in-depth understanding of the strategies and techniques for managing bone loss in revision hip replacement surgeries.

The learning objectives of this webinar are:

• Understand and Apply Bone Defect Classification Systems.
• Optimize Implant Selection for Acetabular Bone Defects.
• Master Current Best Practices for Managing Femoral Bone Loss.
• Enhance Decision-Making Skills in Complex Revision Cases.
• Improve Patient Outcomes through Evidence-Based Approaches.

This Webinar is organised by EFORT independent of any commercial educational support.

EFORT WEBINAR REPLAY AVAILABLE!

The EBOT Exam in a nutshell

The EBOT Exam is jointly organized by the European Union of Medical Specialists (UEMS) and the European Federation of National Associations of Orthopaedics and Traumatology (EFORT). The EBOT Exam has been running since 2001. It is a label of excellence that demonstrates that successful candidates have reached a high level of knowledge in Orthopaedics and Traumatology.

This joint initiative from UEMS and EFORT in education result in a high-quality European Examination for Orthopaedics and Traumatology Surgeons in Europe and beyond.

The EBOT Exam consists in a two-part examination: a written exam held in held in the different examination centres in Europe and as proctored online exam and a presential oral exam.

As per 2025, the European Board of Orthopaedics and Traumatology is pleased to propose its oral examination in three different languages thanks to its close cooperation with the national orthopaedic societies:

• EBOT in English language (Madrid, 27-28 September), organised by EBOT.
• EBOT-TK in Turkish language (Ankara, 25-26 October), organised by TOTBID.
• EBOT-ES in Spanish language (Madrid, 22-23 November), organised by SECOT.

Facing two experienced examiners for 30 minutes, candidates will have to prove their excellence in five disciplines: Basic Science, Paediatrics, Lower Limb, Upper Limb and Spine. Successful candidates will become Fellow of the European Board of Orthopaedics and Traumatology.

EFORT and UEMS wish all the best to candidates and continue to strive for the highest standard of education in Orthopaedics and Traumatology.

MORE INFORMATION & CONTACT

EFORT European Activities Updates

EFORT: Advocating for Orthopaedics and Traumatology at the EU Level

EFORT actively collaborates with EU policymakers directly or through the Biomedical Alliance, to ensure the orthopaedic and trauma community's voice is heard in shaping healthcare and research policies. Through evidence-based proposals, partnerships, and involvement in EU-funded projects and expert committees, EFORT contributes to key initiatives like the Medical Device Regulation and Continuing Medical Education.

The EFORT Committee on European Affairs plays a vital role in monitoring EU developments, fostering collaboration, and positioning our organisation as a key partner in addressing Europe’s health and Research challenges. It conveys concerns and expectations of national associations to European decision-makers.

As trilogue negotiations on the reform of the EU pharmaceutical legislation continue, the Biomedical Alliance calls on EU policymakers to strike the right balance between improving patient access to  medicines, addressing unmet medical needs, and ensuring a sustainable, innovative healthcare system. The revision of the EU pharmaceutical legislation is one of the most extensive reforms in over two decades. The BioMed Alliance stresses the need for legislation that enhances the availability, affordability, and accessibility of medicines across the EU, ensuring that research and innovation translate into real patient benefits.

BioMed Alliance urges decision-makers to:

• Clarify the definition of unmet medical needs to include quality of life and patient-reported outcomes.
• Address medicine shortages through stronger prevention plans and notification requirements.
• Taking a balanced approach in conflict-of-interest policies.
• Enhance research and innovation by supporting drug repurposing and ensuring funding transparency.
• Expand the Role of HERA.
• Safeguard paediatric medicines by prioritising long-term patient outcomes.
• Improve overall access to medicines for European patients.

MORE INFORMATION ON BIOMED ALLIANCE

The CORE-MD (Coordinating Research and Evidence for high-risk Medical Devices) consortium is published new consensus recommendations in The Lancet Regional Health Europe, that set out scientifically robust methodologies for clinical investigations of high-risk medical devices.

These recommendations respond directly to a request from the European Commission to provide expert advice on trial design, addressing a longstanding gap in guidance for the evaluation of high-risk technologies such as cardiovascular implants, orthopaedic devices, and systems for managing diabetes.

Key recommendations from CORE-MD include:

• A four-stage framework for clinical investigations, from initial studies through to long-term follow-up.
• Greater use of randomised controlled trials, including sham-controlled trials with appropriate ethical safeguards.
• Efficient large-scale trials embedded in registries to accelerate evidence generation.
• Mandatory transparency of study design, protocols, and results.
• Tailored approaches for breakthrough or orphan devices, requiring post-market confirmatory studies.

The First Vice-President of EFORT, Professor Rob Nelissen, commented:

"The European Federation of National Societies of Orthopaedics and Traumatology welcomes the CORE-MD recommendation on the design and requirements for clinical investigations of high risk medical devices in Europe. It is crucial that the level of clinical evidence for those medical devices be adjusted to the phase of development and the life cycle of the device. With these recommendation, clear indication on the type of evidence to generate is provided, including leveraging the potential of registries. It is now up to the Medical Device Coordination Group to review the findings and determine whether to capitalise on this Study to create and update existing guidance documents.”

MORE INFORMATION ON CORE-MD

This includes Member State authorities responsible for health at national, regional or local level.

Engagement with organisations representing patients, civil society, healthcare professionals and healthcare providers, researchers, academia, networks of expertise and business is crucial to inform the upcoming 2026 EU4Health Annual Work Programme and for shaping the EU’s strategic direction on public health. 

The results will be compiled in a summary stakeholders’ consultation report.

MORE INFORMATION ON EU4Health

EFORT eScience | Webcasts highlights

This month's selection from the EFORT comprehensive digital library featuring over 19,800 scientific sessions recorded from the past 13 EFORT Congresses.

DOWNLOAD THE EFORT APP

office@efort.org

© 2025 EFORT | All rights reserved
A-One Business Center Z.A. La Pièce 1 - A5
1180 Rolle (VD) | Switzerland
www.efort.org | https://congress.efort.org

This e-mail has been sent to axelle.devun@efort.org
If you do not wish to receive further communication, click here to unsubscribe.